Skip to main content
MainBoardListed
Corona Remedies Limited Logo

Corona Remedies Limited IPO

Corona Remedies Limited IPO

IPO Date :
Issue Price :
Allotment Date :
Listing Date :
List Price :
Lot Size:
Subscription:
Listed Price: ₹ 1,470.00 (+38.42%)

Corona Remedies Limited's successfully transitioned to public market status with its listing on NSE, BSE on 15-12-2025. The IPO mobilized 61,71,102 Shares in cumulative capital, including TBD for corporate expansion and ₹655.37 Cr for shareholder liquidity management.

The public offering was conducted within the price parameters of ₹1,008 to ₹1,062, with minimum investment lots of 14 shares. subscription activity between 08-12-2025 and 10-12-2025 demonstrated market reception to the company's valuation and growth narrative.

The allotment process concluded on 11-12-2025, finalizing share distribution to successful bidders. The listing represents a transformational event, providing the company with enhanced market visibility, regulatory compliance framework, and access to diversified investor capital.

Corona Remedies IPO Details
Lot(s) Distribution

Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.

IPO Reservation
Corona Remedies IPO Key Performance Indicator
Company Financials ( In Crores )

Corona Remedies IPO About Company

Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas including women’s healthcare, cardiology, pain management, urology, and multispecialty segments. As of December 2024, its portfolio includes 67 brands covering women’s health, cardio-diabetic care, pain relief, urology, and multispecialty products such as vitamins, minerals, nutrition, gastrointestinal, and respiratory medications. The company has established a strong pan-India presence with 2,598 medical representatives across 22 states, ensuring deep engagement with healthcare professionals and hospitals. It operates two manufacturing facilities in Gujarat, supporting its production and quality-focused growth strategy in the Indian Pharmaceutical Market.


Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."


Corona Remedies IPO Strength Factors

  1. Leading Market Growth Position: The company is the second fastest-growing among the top 30 pharmaceutical players (MAT 2022–2025), well-positioned to benefit from India’s expanding pharmaceutical demand.
  2. Diversified & Scalable Product Range: Successfully developing multiple “engine brands” across key therapy areas—women’s health, cardio-diabetic, pain, and urology—supports sustainable long-term growth.
  3. Extensive Pan-India Sales Network: A broad national sales and marketing network targeting specialist doctors and mid-income patients drives prescription growth above the overall market rate.

Corona Remedies IPO Risk Factors

  1. High Reliance on Key Therapy Areas: More than 60% of revenue is generated from women’s health, cardio-diabetic, and pain management segments; underperformance or intensified competition in these areas may hinder growth.
  2. Concentration in Major Engine Brands: 27 primary “engine brands” account for over 70% of domestic sales; any decline in top brands like B-29 or Myoril could significantly impact performance.
  3. Dependence on Indian Market: Over 96% of revenue comes from India; weak domestic demand or delays in international expansion could adversely affect financial stability.

Corona Remedies IPO Lead Manager(s)

  • IIFL Securities Limited
  • Jm Financial Limited
  • Kotak Mahindra Capital Company

Corona Remedies IPO Promoter(s)

  1. Dr. Kirtikumar Laxmidas Mehta
  2. Niravkumar Kirtikumar Mehta
  3. Ankur Kirtikumar Mehta

Corona Remedies IPO Company Details

Corona Remedies Limited
Phone:
address:

Corona Remedies IPO Registrar

Bigshare Services Private Limited
Name:
Phone:

Corona Remedies IPO FAQs